First Light Asset Management LLC lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 57.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 300,600 shares of the company’s stock after selling 411,082 shares during the quarter. TransMedics Group accounts for about 4.0% of First Light Asset Management LLC’s portfolio, making the stock its 6th biggest holding. First Light Asset Management LLC owned 0.91% of TransMedics Group worth $45,276,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC purchased a new stake in TransMedics Group during the 2nd quarter worth approximately $301,000. Xponance Inc. acquired a new position in TransMedics Group in the 2nd quarter valued at $306,000. Hood River Capital Management LLC purchased a new position in TransMedics Group in the 2nd quarter valued at $18,854,000. Canada Pension Plan Investment Board acquired a new stake in TransMedics Group during the 2nd quarter worth $16,086,000. Finally, SkyOak Wealth LLC purchased a new stake in shares of TransMedics Group during the second quarter worth $243,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Insider Activity
In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now owns 8,893 shares in the company, valued at $1,353,514.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,247 shares of company stock worth $9,650,880. Corporate insiders own 7.00% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on TMDX
TransMedics Group Trading Down 3.3 %
TMDX opened at $159.50 on Tuesday. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The business has a fifty day simple moving average of $155.95 and a 200-day simple moving average of $130.14. The firm has a market cap of $5.25 billion, a P/E ratio of -469.12 and a beta of 1.99.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s revenue for the quarter was up 117.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) earnings per share. On average, equities analysts expect that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
- Five stocks we like better than TransMedics Group
- 3 Warren Buffett Stocks to Buy Now
- Rate Cut Shockwaves: Which Bank Stocks Will Rise or Fall?
- What is the Dow Jones Industrial Average (DJIA)?
- S&P 500 Shake-Up: New Entrants Driving Market Momentum
- The Role Economic Reports Play in a Successful Investment Strategy
- Don’t Overlook Mosaic’s Challenges—They Might Spark Opportunity
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.